Considerations for setting occupational exposure limits for novel pharmaceutical modalities.

ABSTRACT: In order to develop new and effective medicines, pharmaceutical companies must be modality agnostic. As science reveals an enhanced understanding of biological processes, new therapeutic modalities are becoming important in developing breakthrough therapies to treat both rare and common diseases. As these new modalities progress, concern and uncertainty arise regarding their safe handling by the researchers developing them, employees manufacturing them and nurses administering them. This manuscript reviews the available literature for emerging modalities (including oligonucleotides, monoclonal antibodies, fusion proteins and bispecific antibodies, antibody-drug conjugates, peptides, vaccines, genetically modified organisms, and several others) and provides considerations for occupational h

SUBMITTER: Graham JC 

PROVIDER: S-EPMC7605856 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature